Jump to content

Seribantumab

From Wikipedia, the free encyclopedia
Seribantumab
Monoclonal antibody
Type?
SourceHuman
TargetHER3
Clinical data
Other namesMM-121
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6340H9810N1690O1986S52
Molar mass143151.18 g·mol−1

Seribantumab (INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2] It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.[3]

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

References

[edit]
  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
  3. ^ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y (August 2022). "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?". Biomedicines. 10 (9): 2113. doi:10.3390/biomedicines10092113. PMC 9495728. PMID 36140214.